Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1623 1654
This examiner grants 43% of resolved cases
Examiner Doan Thi-Thuc Phan operates in Art Unit 1613 of Tech Center 1600 and has 653 resolved cases. The allowance rate is 42.7 percent, and the median days to allowance is 1165. These figures suggest a challenging and lengthy prosecution environment. Applicants should be prepared for a rigorous review process that typically takes 1165 days to reach an allowance.
However, the interview lift is a significant 47.7 percent. This suggests that conducting an interview can significantly increase the chances of success compared to the 42.7 percent baseline allowance rate. With 653 resolved cases, the data strongly supports the use of interviews as a primary strategy for overcoming rejections with this examiner. The 47.7 percent lift is a critical metric for practitioners to consider when navigating the complexities of Art Unit 1613 and seeking to improve their overall prosecution outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17018413 | ANTITUMOR AGENT, ANTITUMOR EFFECT ENHANCER, AND ANTITUMOR KIT | Non-Final OA | FUJIFILM Corporation |
| 18680005 | DELIVERY OF SURFACTANT SOLUBLE AGENT | Final Rejection | The Procter & Gamble Company |
| 17596502 | METHODS OF TREATING BILE ACID DIARRHEA | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17423669 | Covered Stent For Local Drug Delivery | Non-Final OA | BIOTRONIK AG |
| 16603359 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17682819 | GEL CREAM EMULSION COSMETIC COMPOSITION WITH HIGH SALT ACTIVES | Non-Final OA | L'OREAL |
| 18716576 | SOLID PARTICLES COMPRISING DECELLULARIZED CARDIAC TISSUE EXTRACELLULAR MATRIX AND METHODS FOR MAKING AND USING THE SAME | Non-Final OA | Case Western Reserve University |
| 17611705 | ISOTROPIC LIQUID CLEANSERS COMPRISING ACYL ISETHIONATE AND METHYL ACYL TAURATE SURFACTANT MIXTURES | Final Rejection | Conopco, Inc., d/b/a UNILEVER |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | Final Rejection | FERTIN PHARMA A/S |
| 17789104 | SILICA MICROCAPSULES | Final Rejection | KAO CORPORATION |
| 17251579 | STABLE CO-FORMULATION OF BENZOYLUREA WITH PYRETHROIDS | Final Rejection | UPL LTD |
| 18255978 | HALOSCENT IN DRY SHAMPOO | Final Rejection | Firmenich SA |
| 18554018 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | Final Rejection | Encapsys, LLC |
| 18475472 | Delivery Particles Based On Amine-Thiol-Ene Conjugates and Derivatives | Final Rejection | Encapsys, LLC |
| 18462537 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | Final Rejection | Encapsys, LLC |
| 18252835 | BIODEGRADABLE DELIVERY PARTICLES | Non-Final OA | Encapsys, LLC |
| 18252822 | BIODEGRADABLE DELIVERY PARTICLES | Non-Final OA | Encapsys, LLC |
| 17322842 | COMPOSITIONS AND METHODS TO DISINFECT, TREAT AND PREVENT MICROBIAL INFECTIONS | Non-Final OA | WIAB WATER INNOVATION AB |
| 18711120 | HYALURONIC ACID FILM WITH EXCELLENT PERCUTANEOUS ABSORPTION AND MANUFACTURING METHOD THEREFOR | Final Rejection | JINWOO BIO CO., LTD. |
| 18015689 | BIODEGRADABLE MICROCAPSULES. PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | Final Rejection | ISP INVESTMENTS LLC |
| 17524709 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | Final Rejection | ELANCO US INC. |
| 18253068 | METHOD FOR PREPARING BIODEGRADABLE MICROCASPULES AND USE OF THE RESULTING MICROCAPSULES | Final Rejection | GEM INNOV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy